K. Muranaka

Development and production of biopharmaceuticals is a growing segment of the pharmaceutical industry. The development of vaccines is only one - but as a result of the current H1N1 flu hysteria it is the most striking - segment of this emerging field. Recombinant proteins, ranging from insulin products to therapeutic antibodies, represent another important group of biopharmaceuticals. With the introduction of the first so-called biosimilars in Europe the demand for highly efficient analysis methods is further increasing. Newly developed stationary phases for the typical modes of biochromatography of native proteins such as SEC or IEC open up new opportunities for increasing throughput in the bioanalytical lab.